Monte Rosa Therapeutics (GLUE) Common Equity (2023 - 2025)
Historic Common Equity for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $245.8 million.
- Monte Rosa Therapeutics' Common Equity rose 1965.37% to $245.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.8 million, marking a year-over-year increase of 1965.37%. This contributed to the annual value of $222.9 million for FY2024, which is 2437.15% up from last year.
- According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Common Equity is $245.8 million, which was up 1965.37% from $268.1 million recorded in Q2 2025.
- Over the past 5 years, Monte Rosa Therapeutics' Common Equity peaked at $275.2 million during Q1 2025, and registered a low of $152.5 million during Q1 2024.
- Moreover, its 3-year median value for Common Equity was $222.9 million (2024), whereas its average is $219.6 million.
- As far as peak fluctuations go, Monte Rosa Therapeutics' Common Equity plummeted by 3742.19% in 2024, and later skyrocketed by 8041.03% in 2025.
- Monte Rosa Therapeutics' Common Equity (Quarter) stood at $179.2 million in 2023, then rose by 24.37% to $222.9 million in 2024, then rose by 10.27% to $245.8 million in 2025.
- Its Common Equity was $245.8 million in Q3 2025, compared to $268.1 million in Q2 2025 and $275.2 million in Q1 2025.